Literature DB >> 3058820

The natural history of human immunodeficiency virus infection.

A R Lifson1, G W Rutherford, H W Jaffe.   

Abstract

Although much is known about the natural history of HIV infection, many issues remain unresolved and require additional study. At least four major questions require further investigation. (1) Current data suggest that most HIV-infected persons will eventually develop AIDS. The proportion of all infected persons who will eventually develop AIDS, as well as the average and maximum incubation periods, have not yet been conclusively defined. (2) Certain clinical signs (such as oral candidiasis) or laboratory test results (such as a depressed T4 count) may indicate a poorer prognosis. However, the predictive value of such indicators for a specific patient and in an individual situation varies. Combinations of clinical and laboratory data may help refine estimates of the likelihood of developing AIDS or other HIV-related diseases. (3) Why some HIV-infected persons develop disease and others do not is not completely understood. The role of cofactors for disease progression needs additional investigation. There may be no one universal cofactor for progression but, rather, various agents that cause immune stimulation and reactivation of latent HIV. Therefore, exposure to a variety of infectious or environmental agents (such as through sexually transmitted diseases or injection of iv drugs) may accelerate progression to disease in HIV-infected persons. (4) It is not established whether antiviral agents will prevent or reduce the likelihood of disease progression in asymptomatic HIV-infected persons. If beneficial, should they be given to all HIV-infected persons or only to those whose clinical and laboratory evaluation suggests an increased likelihood of progression? Given these uncertainties, how should the physician or other health care worker evaluate, treat, and counsel the HIV-infected patient? Such patients should receive a comprehensive medical evaluation for both diagnostic and staging purposes; the details of such an evaluation are beyond the scope of this review and have been well described. A few brief points, however, should be emphasized.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3058820     DOI: 10.1093/infdis/158.6.1360

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Course of HIV-I infection in a cohort of homosexual and bisexual men: an 11 year follow up study.

Authors:  G W Rutherford; A R Lifson; N A Hessol; W W Darrow; P M O'Malley; S P Buchbinder; J L Barnhart; T W Bodecker; L Cannon; L S Doll
Journal:  BMJ       Date:  1990-11-24

2.  UV activation of human immunodeficiency virus gene expression in transgenic mice.

Authors:  J Vogel; M Cepeda; E Tschachler; L A Napolitano; G Jay
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals.

Authors:  J Homsy; M Meyer; J A Levy
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

4.  Neopterin and alpha and beta interleukin-1 levels in sera of patients with human immunodeficiency virus infection.

Authors:  M M Reddy; M H Grieco
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

5.  Derivation of neurotropic simian immunodeficiency virus from exclusively lymphocytetropic parental virus: pathogenesis of infection in macaques.

Authors:  D P Sharma; M C Zink; M Anderson; R Adams; J E Clements; S V Joag; O Narayan
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

6.  Beta 2-microglobulin and neopterin: predictive markers for human immunodeficiency virus type 1 infection in children?

Authors:  M M Chan; J M Campos; S Josephs; N Rifai
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

7.  Candida albicans biotypes in human immunodeficiency virus type 1-infected patients with oral candidiasis before and after antifungal therapy.

Authors:  M Bruatto; V Vidotto; G Marinuzzi; R Raiteri; A Sinicco
Journal:  J Clin Microbiol       Date:  1991-04       Impact factor: 5.948

Review 8.  Caring for patients with HIV infection. Management plan for family physicians.

Authors:  G Bally
Journal:  Can Fam Physician       Date:  1993-10       Impact factor: 3.275

9.  Dissociation of unintegrated viral DNA accumulation from single-cell lysis induced by human immunodeficiency virus type 1.

Authors:  L Bergeron; J Sodroski
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

Review 10.  HIV infection and surgeons.

Authors:  E Y Lin; F C Brunicardi
Journal:  World J Surg       Date:  1994 Sep-Oct       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.